## **TELDAY**

## For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory

Abbreviated Prescribing information for TELDAY (Telmisartan 20/40/80mg Tablets) [Please refer the complete prescribing information available at www.torrentpharma.com]

**PHARMACOLOGICAL PROPERTIES**: Telmisartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin ll by selectively blocking the binding of angiotensin ll to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland.

**INDICATION:** For the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents

**DOSAGE AND ADMINISTRATION:** Dosage must be individualized. The usual starting dose of Telmisartan is 40 mg once a day. Blood pressure response is dose related over the range of 20-80 mg. It is administered with or without food.

**CONTRAINDICATION:** In patients who are hypersensitive to any component of this formulation.

WARNINGS & PRECAUTIONS: When pregnancy is detected, Telmisartan should be discontinued as soon as possible. The use of drugs that act directly on the renin angiotensin system during the second and third trimesters of pregnancy has been associated with fetal and neonatal injury, including hypotension, neonatal skull hypoplasia, symptomatic hypotension, anuria, reversible or irreversible renal failure, and death. Oligohydramnios has also been reported, presumably resulting from decreased fetal renal function, oligohydramnios in this setting has been associated with fetal limb contractures, craniofacial deformation, and hypoplastic lung development. Caution should be exercised in patients with biliary obstructive disorders or hepatic insufficiency. Dual blockade of the RAS with angiotensin-receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.

## **DRUG INTERACTIONS:** Digoxin and warfarin.

**SADVERSE REACTIONS:** Impotence, increased sweating, flushing, fever, leg pain, malaise, palpitation, dependent edema, angina pectoris, tachycardia, leg edema, abnormal ECG, insomnia, somnolence, migraine, vertigo, paresthesia, involuntary muscle contractions, hypoaesthesia, flatulence, constipation, gastritis, vomiting, dry mouth, hemorrhoids, gastroenteritis, enteritis, gastroesophageal reflux, toothache, non-specific gastrointestinal disorders, gout, hypercholesterolemia, diabetes mellitus, arthritis, arthralgia, leg cramps, anxiety, depression, nervousness, asthma, bronchitis, rhinitis, dyspnea, epistaxis, dermatitis, rash, eczema, pruritus, micturition frequency, cystitis, abnormal vision, conjunctivitis, tinnitus and earache.

## **MARKETED BY:**



TORRENT PHARMACEUTICALS LTD. Torrent House, Off Ashram Road, Ahmedabad-380 009, INDIA

IN/TELDEY 20,40,80mg/Aug-15/01/AbPI

(Additional information is available on request)